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Introduction
The somatic mutations in a cancer genome are the aggregate outcome of one or more mutational 
processes operative through the life of the cancer patient1-3. Each mutational process leaves a 
characteristic mutational signature determined by the mechanisms of DNA damage and repair that 
constitute it. A role was recently proposed for the APOBEC family of cytidine deaminases in 
generating particular genome-wide mutational signatures1,4 and a signature of localized 
hypermutation called kataegis1,4. A germline copy number polymorphism involving APOBEC3A 
and APOBEC3B, which effectively deletes APOBEC3B5, has been associated with a modest 
increased risk of breast cancer6-8. Here, we show that breast cancers in carriers of the deletion 
show more mutations of the putative APOBEC-dependent genome-wide signatures than cancers in 
non-carriers. The results suggest that the APOBEC3A/3B germline deletion allele confers cancer 
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susceptibility through increased activity of APOBEC-dependent mutational processes, although 
the mechanism by which this occurs remains unknown.
In recent analyses of somatic mutational signatures in 21 whole-genome sequenced primary 
human breast cancers1, two signatures characterized by C>T and/or C>G mutations at 
TpCpX trinucleotides were identified (the underlined base is the mutated base and X can be 
any base). These were subsequently observed in several other cancer types (Fig. 1A, Online 
methods) and are among the commonest mutational signatures found in human cancer 
(Supplementary Figures 3A-B)1,9. These signatures have been designated Signatures 2 and 
13 (according to the nomenclature of Alexandrov et al 2013)9. Signature 2 is composed 
predominantly of C>T transitions with fewer C>G transversions at a TpCpX sequence 
context. In contrast, Signature 13 is dominated by C>G transversions at a TpCpX context1,9. 
A subset of breast, and other, cancer cases have an extremely large number of mutations of 
these signatures and we have called these “hypermutators”1,9.
The features of the mutations associated with Signatures 2/13 resemble those of mutations 
generated by the AID/APOBEC family of cytidine deaminases10,11. Members of this gene 
family have important physiological roles in antibody diversification (AICDA) and 
restriction of retroviruses and mobile retro-elements (e.g. APOBEC3A, APOBEC3G) 
[reviewed11-13]. However, it has been suggested that their DNA editing capabilities could 
also underlie undesirable mutagenesis leading to cancer4,11,14,15. Indeed, in addition to 
AICDA, the capacity for editing of nuclear DNA has been demonstrated for 
APOBEC3A14,16,17, APOBEC1, APOBEC3C and APOBEC3G10.
A common germline copy number deletion polymorphism involving the APOBEC3 gene 
cluster on chromosome 22 (Fig. 1B) has been associated with an elevated risk of breast 
cancer. A copy number genome-wide association study (GWAS) of 16,000 cases of eight 
common diseases highlighted this deletion polymorphism in association with breast cancer 
in a primary screen although it did not validate in replication6. Subsequently, a GWAS in 
the Chinese population demonstrated an association with breast cancer (odds ratio (OR) 1.3 
one-copy, 1.8 two-copy deletion, p=2.0×10−24)7 that was replicated in a European 
population (OR 1.2 one-copy, 2.3 two-copy deletion, ptrend = 0.005)8. The deletion allele has 
a frequency of ~8% in European populations5,6, 37% in East Asians and 93% in Oceania5. 
The ~29,500bp genomic deletion has delimiting breakpoints in APOBEC3A and 
APOBEC3B (which are adjacent to each other and in the same orientation on chromosome 
22) and results in a chimeric APOBEC3A/3B gene. This hybrid gene is predicted to produce 
a transcript which is predominantly constituted of APOBEC3A sequence but replaces the 
APOBEC3A 3′UTR with the APOBEC3B 3′ UTR (Supplementary Note) and encodes a 
protein which has an identical amino acid sequence to APOBEC3A5 (Fig. 1B). Homozygous 
carriers of this deletion allele are predicted not to make any APOBEC3B protein. Given its 
association with breast cancer, we explored the relationship between the deletion allele 
(Table 1) and the presence of mutational signatures 2/13.
We aggregated a set of 923 breast cancers from multiple different sequencing centres in 
which normal and neoplastic tissues had been sequenced for somatic mutations, 123 whole-
genome and 800 whole-exome (Supplementary Table 1A-B). Using next-generation 
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sequence (NGS) data, we identified 128 patients who were heterozygous and 14 who were 
homozygous for the APOBEC3A/3B deletion allele (Online methods, Supplementary Note, 
Supplementary Fig 4A-C, Supplementary Table 2A-C). Applying the non-negative matrix 
factorization (NNMF) algorithm employed to extract mutational signatures1,9,18 to the 
somatic mutations, we estimated the numbers and the proportional contribution of mutations 
attributable to each mutational signature in each cancer case (Supplementary Figure 1C-1O, 
Supplementary Table 1B). Combining these two sets of results, we observed that cancers 
with a higher mutational burden of Signatures 2/13 were more likely to be derived from 
patients who were carriers of at least one copy of the germline APOBEC3A/3B deletion 
allele (Wilcoxon rank-sum test p=1.7e−3, Online methods, Supplementary Note, 
Supplementary Figure 3B, E). In particular, the subset of hypermutator cancers19 
(Supplementary Table 3A) is associated with the deletion allele. Breast cancers from 
individuals who are heterozygous or homozygous for the APOBEC3A/3B deletion allele 
have a relative risk of 2.37 (CI 1.64-3.46) of being hypermutators compared to breast 
cancers from individuals who do not carry the deletion allele (Table 1, Cochrane-Armitage, 
p=6.251e−6). By contrast, no association was found between the deletion allele and 
Signature 1, another mutational signature common in breast and other cancers (p=0.935). 
The results therefore suggest that the APOBEC3A/3B deletion allele is specifically 
associated with the burden of Signatures 2/13 mutations in breast cancer (Table 1, 
Supplementary Note, Supplementary Table 3B addressing population stratification).
We then examined 1769 cancers of eleven other cancer types in which Signature 2/13 
mutations have been found (Table 2, Supplementary Figure 3B-D)11. Of forty patients with 
acute lymphoblastic leukaemia three were hypermutators (Table 2) and all were carriers of 
the germline deletion allele, two heterozygous and one homozygous (p=2.51e−5). 
Enrichment for hypermutators among patients who were heterozygous and homozygous for 
the deletion allele was also seen in bladder carcinoma, although this did not reach statistical 
significance (p=0.038, Bonferroni corrected p=0.452, Table 2). Thus, the APOBEC3A/3B 
deletion allele may be associated with the Signature 2/13 mutation burden in cancers other 
than breast.
In breast and other cancers, several non-carriers of the germline deletion allele had large 
numbers of Signature 2/13 mutations (Table 2, Supplementary Table 3B). Similarly, several 
carriers of the deletion allele did not show large numbers of Signature 2/13 mutations in 
their cancers (Online methods). It thus appears that the germline deletion allele is neither 
necessary nor sufficient to generate Signature 2/13 mutations. This behaviour is in-keeping 
with that of a germline susceptibility allele, which has a modest effect on a quantitative trait. 
Indeed, the marked variation in Signature 2/13 mutation prevalence between different 
cancers (Supplementary Figure 3C-D) would suggest that multiple factors are likely to 
influence the burden of Signature 2/13 mutagenesis, such as APOBEC gene inherited 
variation, APOBEC gene expression, virus/transposon activity and inflammation, and that 
these may vary in importance in different cancers.
If Signatures 2/13 are due to APOBEC activity, they should bear the known characteristics 
of the mutations generated by these enzymes. The substitution classes in Signatures 2/13 
(C>T transitions and C>G transversions) coupled with the TpC sequence context were 
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responsible for the initial proposition of the role of this enzyme family1. However, 
APOBEC-induced mutations exhibit other distinctive characteristics, including preferential 
cytosine to uracil deamination on stretches of single-stranded DNA20-22. Consequently, 
adjacent APOBEC-induced mutations often arise on the same parental allele (i.e. are in cis 
with each other) and are on the same DNA strand (i.e. successive mutations may be C>T…
C>G…C>T or G>A…G>C…G>A but not C>T…G>A…C>T), a pattern referred to as 
“strand-coordinated mutagenesis” (Online methods, Supplementary Note).
To investigate the presence of strand-coordinated mutagenesis in Signatures 2/13 
(Supplementary Figure 4A-C), we examined the frequency of two successive mutations 
arising on the same strand and on different strands in the 123 breast cancers which had been 
whole-genome sequenced. Several cancers demonstrate more strand-coordinated pairs of 
mutations than expected by chance (corrected for mutation spectrum and mutation burden, 
Fig. 2A) and this is directly correlated to the proportion of Signature 2/13 mutations in these 
cancers (Fig. 2B, r=0.74, p=1.1e−21). Furthermore, examination of NGS reads in these 
cancers show that strand-coordinated mutations are usually in cis (Supplementary Note, 
Supplementary Table 4, Supplementary Figure 4D, p<0.0001), confirming that they are 
linked to each other on the same parental haplotype. Together, these findings are compatible 
with the model that Signature 2/13 mutations often arise on stretches of single-stranded 
DNA similar to mutations induced by APOBEC enzymes4,20.
The association between the germline APOBEC3A/3B deletion allele and Signature 2/13 
mutation burden (OR 2.68 one-copy, 3.82 two-copy deletion, ptrend 6.251e−6; combined OR 
2.78 CI 1.75-4.41) is in-keeping with the reported modest increased risk of breast cancer 
conferred by the deletion allele based on GWAS. However, the mechanism by which the 
germline APOBEC3A/3B fusion confers elevated APOBEC mutagenic activity is unclear. 
The amino acid sequence of the predicted fusion protein is identical to APOBEC3A, 
although the transcript is a chimaera of APOBEC3A and a segment of the APOBEC3B UTR 
and this could confer altered transcriptional or translational regulation of APOBEC3A. The 
other consequence of the APOBEC3A/3B germline deletion allele is deletion of the 
APOBEC3B coding sequence and thus absence of APOBEC3B in homozygous patients 
(Supplementary Figure 5A). It is not immediately clear, however, how this would directly 
increase APOBEC-related mutagenesis.
The TpC sequence context of mutations generated by APOBEC123,24, APOBEC3A22 and 
APOBEC3B22,25,26 closely mirrors the sequence context of Signature 2/13 mutations in 
human cancers indicating that these particular members of the APOBEC enzyme family are 
likely candidates for generating these mutational signatures4,22. Thus far, there have been no 
recurrent somatic mutations identified within the APOBEC gene family that can be 
associated with Signature 2/13. Based on gene expression studies, recent reports have 
suggested that APOBEC3B is responsible27,28,29. However, the existence of Signature 2/13 
hypermutator breast cancers in individuals with germline homozygosity for the 
APOBEC3A/3B deletion allele, which completely removes APOBEC3B coding sequences 
(Fig. 1B) and in which APOBEC3B expression is absent (Online methods, Supplementary 
Note, Supplementary Fig 5A-B)30, indicates that over-activity of APOBEC3B is unlikely to 
be exclusively responsible for Signatures 2/13 mutations.
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The burden of somatic mutations due to Signatures 2/13 is one of the highest attributable to 
any mutational signature across the spectrum of human cancer11. Thus, elucidation of the 
mechanisms underlying Signatures 2/13 will advance understanding of carcinogenesis in 
several cancer types and potentially influence strategies for cancer prevention and treatment. 
The effect of the APOBEC3A/3B germline deletion allele on the Signature 2/13 mutation 
burden reported here provides independent evidence for the underlying role of members of 
the APOBEC gene family in generating these mutations. Furthermore, it provides a 
plausible biological mechanism by which this breast cancer predisposition allele could 
confer its effect. The geographic variation in population frequency of the APOBEC3A/3B 
germline deletion allele5 suggests that there may be selection in favour of it (Online 
methods). Since some APOBECs are involved in innate immunity4,11 to infection it may be 
that protection to infection is conferred by the deletion allele. This may be balanced, to some 
extent, by predisposition to cancer. If true, this would be remarkable since both effects 
would be mediated by the same underlying mechanism; the double-edged sword of the 
mutagenic activity of the APOBEC proteins.
Online methods
1. Background information
Next-generation whole-genome and exome-sequenced cancer samples were previously 
sequenced by members of the International Cancer Genome Consortium, The Cancer 
Genome Atlas and other centres9,18. High-confidence somatic substitutions were obtained 
from these consortia or other peer-reviewed publications not related to these consortia, 
filtered further for potential false positive calls using dbSNP, 1000 genomes, the NHLBI GO 
Exome Sequencing Project, the 69 Complete Genomics panel as well as a bespoke panel of 
BAM files of unmatched normal tissues containing more than 120 normal genomes and 500 
exomes9. These data were then parsed through an algorithm previously developed to extract 
mutational signatures in human cancers18 called Non-negative Matrix Factorisation 
(NNMF)9,18.
Six main substitution classes (C>A:G>T, C>G:G>C, C>T:G>A, T>A:A>T, T>C:A>G and 
T>G:A>C) were subdivided according to the 5 prime and 3 prime flanking sequence 
context. Since there are six classes of base substitution and 16 possible sequence contexts 
for each mutated base (A, C, G or T at the 5′ base and A, C, G or T at the 3′ base), there are 
96 possible mutated trinucleotides for each cancer. Herewith, the convention for describing 
a mutated trinucleotide will be XpCpX, where X can be any base and the mutated base is 
underlined1,2,9,18.
A total of 7,042 samples were analyzed from 30 types of cancer. 21 distinct mutational 
signatures were extracted. The commonest signatures were Signature 1A and Signature 1B, 
both characterized by C>T mutations at a XpCpG trinucleotide (Supplementary Figure 1A), 
and Signature 2 and Signature 13, characterized by dominant C>T transitions at a TpCpX 
sequence context in Signature 2 and C>G transversions at a TpCpX sequence context in 
Signature 13 (Supplementary Figure 1A-B)1,2,9,18. Signatures 1A/1B are likely to be caused 
by deamination at methylated CpGs whereas Signatures 2/13 are thought to be due to the 
APOBEC family of cytidine deaminases. Therefore, for the purposes of this analysis, 
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Signatures 2 and 13 are considered together. NNMF is able to estimate the number of 
mutations associated with extracted mutation signatures for individual cancers in a given set 
of samples (summarized in Supplementary Table 1B, Figure 1C-1O).
In this analysis, a total of 2,719 samples were previously characterized by NNMF and also 
had BAM files available for inspection (Supplementary Table 1A-B). BAM files were 
downloaded from CGhub (https://cghub.ucsc.edu/) between 9 May 2013 and 26 June 2013. 
For the ease of tracking samples through this analysis, we have kept the naming convention 
attached to the cancer sample for tables and figures, even if the germline deletion 
polymorphism was sourced from a matched normal because the signatures of somatic 
mutagenesis will have been identified in the tumor samples in the first place. This is also for 
the purpose of continuity between publications. For samples originating from the Sanger 
Institute, PDXXXX denotes a specific individual, with suffix “a”,”c” or “d” denoting tumor 
samples and suffix “b” for the matched normal sample.
2. Detection of germline APOBEC3A/3B deletion polymorphism
In order to detect this deletion polymorphism from next-generation sequencing data, 
multiple loci within and flanking the coordinates of the deletion were sampled 
(Supplementary Figure 2A, Supplementary Table 2A) from BAM files (overall workflow 
and directions to processing data in Supplementary Figure 2B). Raw short read data had 
been aligned back to the reference genome (NCBI build 37) with duplicates and unmapped 
reads removed. Externally sourced BAM files were sourced from the TCGA data hub 
https://browser.cghub.ucsc.edu/.
Matched normal BAM files were sought for calling this deletion allele. However, a tumor 
BAM file was used if a normal BAM was not available (Supplementary Table 2B). Samples 
that did not have BAM files available for examination were excluded from analysis. In total, 
the APOBEC3A/3B polymorphism detection was sourced from 561 tumors (99 BLCA, 117 
BRCA, 1 CESC, 19 HNSC, 2 KIRP, 303 LUAD, 12 STAD, 2 THCA and 6 UCEC) and 
2158 normals.
For samples with whole genome data, the expected sequencing depth in the absence of the 
deletion polymorphism, i.e. wild-type copy number (CN) of 2, d2, was calculated as the 
average depth of the 60 loci in the flanking regions. The expected depth in the presence of a 
heterozygous deletion allele, d1, is then given by d1 = d2 / 2 and the expected depth in the 
presence of a homozygous deletion allele, d0, was set to the expected number of misreads, 
estimated as d2/20. A maximum likelihood test was performed to identify the most likely 
CN from the set 31, with corresponding expected depths represented as Poisson distributions 
{Pois(d0), Pois(d1), Pois(d2)}, given the observed sequencing depths within the region of the 
deletion polymorphism (Supplementary Dataset 1).
For exome-sequenced samples, an expectation-maximisation algorithm was utilized, with 
the copy number (CN) of each sample and the ratio of sequencing depth within and outside 
the deletion polymorphism used as latent variables. The CN of each sample was initialized 
as 2 and the depth ratio of loci within the deletion polymorphism region to those outside, r, 
was modelled non-parametrically by bootstrap resampling (n=1000). For samples with CN 
Nik-Zainal et al. Page 6
Nat Genet. Author manuscript; available in PMC 2014 November 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
of 2, 1 and 0, respectively, the expected depths within the deletion polymorphism region are 
then given by
At each maximisation step, the copy number of each sample was assigned as that whose 
distribution showed most overlap with din for that sample, after bootstrap resampling. At 
each expectation step, r was recalculated using bootstrap resampling of loci within just those 
samples classified as CN=2 in the previous maximisation step. The EM algorithm was 
continued until no samples were reclassified from one iteration to the next, or for a 
maximum of 100 iterations (Supplementary Figure 2B, Supplementary Dataset 2).
The results of the calling of the polymorphism status in all the samples is provided in 
Supplementary Table 2B. The reproducibility of the calling method was sought by 
examining the concordance between calling on the tumor and normal BAM files from the 
same patient (Supplementary Note, Supplementary Table 2C, Supplementary Figure 2C) as 
well as concordance between genome- and exome-sequenced samples in the same patient.
3. The relationship between the APOBEC3A/3B germline deletion allele and somatic 
mutational signatures in cancer
The dataset comprised genome-sequenced (123) as well as exome-sequenced (800) cancers. 
In order to perform the analyses, the rate of mutation was calculated for each cancer (rate of 
Signature 2/13 per Mb), correcting for whether the samples had been genome- or exome-
sequenced.
Because the rates of Signatures 2/13 were not normally distributed (Supplementary 3A-D), a 
one-sided Wilcoxon rank-sum test was performed to see whether carrying one copy of the 
deletion allele had an overall effect on the mutation rate of the signatures.
We sought to include more cancer samples in order to increase the power of the analyses. 
There were no further available breast cancer samples with BAM files ready for download, 
hence we sought inclusion of other cancer types that had previously been analyzed9,18. 
However, it was noted that the distribution of rates of Signatures 2/13 varied considerably 
between cancer-types (Supplementary Figure 3B-D) and clear outliers were present in all the 
cancer types skewing the distribution of mutation rates (Supplementary Figure 3A,D-E).
Some cancers were observed to have a strikingly high proportion of total mutations 
associated with Signatures 2/13 and/or have higher rates of mutagenesis associated with this 
signature (Supplementary Figure 1C-1O, 5B). Using the rate of Signatures 2/13 
mutagenesis, outliers were identified as patients with cancers that had a mutation rate 
exceeding 1.5 times the length of the interquartile range from the 75th percentile for each 
type of cancer19. These outliers will hitherto be referred to as “hypermutators” although we 
do not suggest that there is an on-going biological process attached to this name. Given the 
considerable variation of the mutation rates for different cancer tissue-types (Supplementary 
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Figure 1A,1B), each cancer type was analyzed separately. A summary of the hypermutators 
versus non-hypermutators is provided in the Supplementary Table 3A.
4: Strand-coordinated mutagenesis
In theory, neighboring mutations could arise on either of two strands of a double-helix 
(Supplementary Figure 4A) particularly if they had arisen as independent events during 
different cycles of cell division. If more mutations are observed to occur on the same strand 
than expected by chance (Supplementary Figure 4B), this would imply one of two scenarios: 
Either those neighboring mutations arose over different rounds of cell division with 
preferential targeting of one strand over another or they arose during a single round of cell 
division and potentially occurred in the same instance.
We therefore sought to formally document that neighboring mutations are occurring on the 
same strand more often than expected or “strand-coordinated mutagenesis”. In order to 
demonstrate genome-wide strand coordination, analysis was carried out on all whole-
genome sequence data for which BAM files were available (Supplementary Table 4A). 
Given a set of mutations, each occurring at a base of type (A, C, G, T) on the + strand, we 
identify all pairs of mutations and classify them as ‘same’ if both mutations are of the same 
originating base and ‘diff’ if not (i.e. first and second mutations of each pair respectively: 
A>X and A>X; G>X and G>X; C>X and C>X; and T>X and T>X, with no prior selection 
for mutations at a TpC context and where X can be any base). The distance between 
successive pairs or intermutation distance is also calculated (Supplementary Figure 4C).
The proportion of pairs of mutations that are expected to occur on the same base assuming 
randomly ordered mutations is given by , where pX is the fraction of 
mutations that occur at nucleotide X. To depict the deviation of the observed pairs of 
mutations found on the same strand from that of the expected pairs of mutations on the same 
strand, a standard Forest plot was constructed (data of expected and observed same strand 
mutations for all 124 samples are provided in Supplementary Table 4A, columns B-E). For 
the reason of space, only a subset of samples were presented in Figure 2A.
Because same-strand mutations were ascertained in an unbiased way from any mutation type 
(not restricted to just cytosine mutations at TpCs), to see whether strand-coordinated 
mutations were a particular feature of Signatures 2/13, we sought a relationship between the 
degree of “strand-coordination”, given by the OR of strand-coordination, and the fractional 
burden of Signatures 2/13 in each cancer (Supplementary Figure 4D).
We sought additional characteristics of the mutations in the whole-genome sequenced breast 
cancers that support the suggestion that mutations associated with Signatures 2/13 have 
arisen due to the APOBEC family of enzymes (Supplementary Note, Supplementary Figure 
4D, Supplementary Table 4).
5: Relationship between expression of APOBEC family members and rates of mutation of 
Signatures 2/13
RNA-seq derived expression data was obtained from the https://browser.cghub.ucsc.edu/ for 
relevant samples. In total, there were 1691 patients for whom comparable data were 
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obtainable. Expression levels for each APOBEC family member were standardized relative 
to the levels of TBP (TATA-binding protein) and the relationship between the APOBEC3B 
expression levels and germline deletion allele status in these cancers (Supplementary Figure 
5A-B, Supplementary Table 5A).
6. Selection for the APOBEC3A/3B deletion
The germline APOBEC3A/3B deletion polymorphism highlighted in this analysis was 
reported to display a strikingly differentiated worldwide distribution of allele frequencies5. 
The FST value (measuring population differentiation) was re-examined using the reported 
deletion allele frequencies and additional SNP genotype data from the CEPH-HGDP panel 
published after the CNP study32. This value will depend on the way the populations are 
grouped, and needs to be compared with other variants of similar frequency to measure how 
unusual it is. We used two published grouping schemes, into five continental geographical/
genetic groups (1. Sub-Saharan Africans, 2. Middle Easterners plus Europeans, 3. East 
Asians, 4. Native Americans and 5. Oceanians) or into 32 population groups33, and matched 
SNP frequencies measured as minor allele frequency to ± 0.1%. For the five continental 
groups, FST was 0.330 (97.4th percentile compared with 2,716 frequency-matched SNPs), 
and for the 32 population groups it was 0.285 (96.6th percentile compared to 2,059 
frequency-matched SNPs). The level of population differentiation was thus higher than 
expected by chance, which can result from positive selection34, and we therefore examined 
other statistics sensitive to positive selection. Cross-population extended haplotype 
homozygosity (XP-EHH) and integrated haplotype score (iHS) values were obtained from 
the HGDP Selection Browser (http://hgdp.uchicago.edu/). These haplotype-based tests for 
positive selection35 utilise information 500kb upstream and downstream of the deletion, and 
thus the two sides can be examined separately. Neither side showed any significantly high 
XP-EHH (>2.5) or iHS value (∣iHS∣>2.0) in any continental group or individual population. 
Finally, we looked at allele frequency spectrum-based tests (Tajima’s D, Fay & Wu’s H and 
Nielsen et al.’s Composite Likelihood Ratio test) using the 1000 Genomes Phase 1 re-
sequenced data in the East Asian populations (CHB, CHS and JPT) (1000G Phase 1)36 in 
the regions surrounding the deletion, as described (1000G Pilot)31. There was no evidence 
for positive selection in these populations, although in this case, the power of these tests is 
limited because the frequency of the deletion in these populations is not high enough.
Overall, this locus shows unusually high differentiation among continents and populations. 
However, there remains a lack of other evidence for positive selection and so we cannot 
convincingly conclude that this deletion has been positively selected in human populations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The APOBEC3A/3B germline deletion polymorphism is associated with an increased 
burden of presumptive apobec-related signatures
(A) Signatures 2 and 13 extracted by Non-negative Matrix Factorization11 share sequence-
specific mutation characteristics to members of the AID/APOBEC family of cytidine 
deaminases. Both signatures are characterized by C>T transitions and/or C>G transversions 
at a TpCpX sequence context. Signature 2 is dominated by C>T transitions. Signature 13 is 
dominated by C>G transversions. (B) The APOBEC3A/3B hybrid deletion allele. The genes 
are in tandem on chromosome 22. The polymorphism involves a deletion of the APOBEC3B 
coding sequence fusing the 3′UTR of APOBEC3B to the 3′UTR of APOBEC3A.
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Figure 2. Additional features of Signatures 2/13 that are similar to mutagenic patterns of 
APOBECs
(A) Several cancers showed an excess of mutations arising on the same strand or strand-
coordinated mutagenesis. For reasons of space only a subset of cancers is depicted here. 
Odds ratio (OR) of observed strand-coordinated mutations over expected is presented (as a 
red box) with 95% confidence intervals (grey line). The OR was calculated from the 
observed number of same strand/different strand mutations divided by the number of 
expected same strand/different strand mutations (where the expected numbers were 
corrected for the overall mutation rate of the cancer and the mutation spectra). A higher OR 
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indicates more same strand mutations than expected. Patients highlighted in red have 
hypermutator breast cancers. (B) A direct correlation is seen between the OR of strand-
coordinated mutagenesis and the fractional burden of Signatures 2/13. Patients who are 
homozygous/heterozygous for the deletion allele are highlighted (red dots) to show the 
enrichment of deletion carriers amongst breast cancers with a high burden of Signatures 
2/13.
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Table 1
In the cohort of 923 breast cancers, the majority of patients had a mutation rate of 
Signatures 2/13 of less than 1 per Mb
A subset of patients had mutations comprising mostly (or in some cases entirely) of Signatures 2/13 with a 
very high mutation rate associated with these signatures (hypermutators). A higher proportion of patients were 
found to be carriers of at least one copy of the germline deletion allele from amongst patients who had 
hypermutator breast cancers. A test for trend demonstrates a correlation between the number of copies of the 
deletion allele in a breast cancer patient and having a hypermutator breast cancer (p=6.251e−5).
deletion allele status hypermutators non-hypermutators total hypermutators/total cases
homozygous 4 10 14 0.286
heterozygous 28 100 128 0.219
non-carrier 74 707 781 0.095
Cochrane-Armitage test for trend p=6.251e-6
Chi-statistic 20.4098
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Table 2
Relationship between number of copies of the deletion allele and the burden of Signatures 
2/13
A trend was seen for ALLs but not for other cancers (test for trend).
hypermutator non-hypermutator cancer type test for trend Bonferroni
cancer type hom het non total hom het non total total chi-statistic p-value correction
ALL 1 2 0 3 0 5 32 37 40 17.756 2.51E-05 3.01E-04
BLCA 0 3 6 9 0 13 114 127 136 4.3192 0.03769 4.52E-01
BRCA 4 28 74 106 10 100 707 817 923 20.4098 6.25E-06 7.50E-05
CESC 0 1 3 4 0 5 29 34 38 0.2852 0.5933 -
HNSC 0 3 33 36 0 33 229 262 298 0.5413 0.4619 -
KIRP 0 0 5 5 0 14 81 95 100 0.8568 0.3546 -
LUAD 0 3 22 25 0 18 260 278 303 1.0856 0.2975 -
LUSC 0 3 12 15 0 17 133 150 165 0.9616 0.3268 -
MM 0 0 2 2 2 10 51 63 65 0.4152 0.5193 -
STAD 0 1 10 11 0 18 104 122 133 0.2643 0.6072 -
THCA 0 1 19 20 0 44 220 264 284 1.8977 0.1683 -
UCEC 0 0 12 12 4 35 183 222 234 2.319 0.1278 -
Total 5 45 198 248 16 312 2143 2471 2719 10.9215 9.51E-04 -
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